Intelligence / Healthtech / New Clinical Trials / CSPC Megalith Biopharmaceutical Co.,Ltd.
CSPC Megalith Biopharmaceutical Co.,Ltd.
9 Nov 2026: Trial registered · Immunogenicity and Safety of SYS6057 in the Participants Aged 18 Years and Above. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 9 Nov 2026
- Title
- Immunogenicity and Safety of SYS6057 in the Participants Aged 18 Years and Above
- Conditions
- Lower Respiratory Tract Disease Caused by RSV Infection
- Phase
- Phase 1
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Reference
- NCT07925775
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at CSPC Megalith Biopharmaceutical Co.,Ltd.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for CSPC Megalith Biopharmaceutical Co.,Ltd. in our registers.
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.